DeepMed Research

SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: QIV-HD by IM
Biological: QIV-HD by SC
Biological: QIV-SD by SC

First Posted Date: 2017-07-28

Last Posted Date: 2022-04-04

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 175

Registration Number: NCT03233217

Locations: 🇯🇵
Sanofi Pasteur Investigational Site, Ōsaka, Japan

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Phase 2

Completed

Conditions: Meningitis
Meningococcal Meningitis
Meningococcal Infections

Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Biological: Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine

First Posted Date: 2017-07-02

Last Posted Date: 2022-04-04

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 188

Registration Number: NCT03205358

Locations: 🇫🇮
Investigational Site Number 005, Espoo, Finland
🇫🇮
Investigational Site Number 002, Helsinki, Finland
🇫🇮
Investigational Site Number 006, Helsinki, Finland

and more 5 locations

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Phase 3

Completed

Conditions: Meningitis, Meningococcal

Interventions: Biological: MMR
Biological: MenACYW conjugate vaccine
Biological: PCV13
Biological: Varicella
Biological: DTaP-IPV-HB-Hib

First Posted Date: 2017-07-02

Last Posted Date: 2022-04-05

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1183

Registration Number: NCT03205371

Zika Case Definition and Surveillance Study

Completed

Conditions: Zika Virus Disease

First Posted Date: 2017-05-18

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 2400

Registration Number: NCT03158233

Locations: 🇭🇳
Investigational site, Tegucigalpa, Honduras
🇵🇷
Investigational Site, Carolina, Puerto Rico

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

Phase 2

Completed

Conditions: Rabies Virus

Interventions: Biological: VRVg 2
Biological: Imovax Rabies
Biological: VRVg 1
Biological: Human Rabies Immunoglobulins (HRIG)

First Posted Date: 2017-05-09

Last Posted Date: 2022-04-19

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 320

Registration Number: NCT03145766

Locations: 🇺🇸
Investigational Site, Las Vegas, Nevada, United States

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Phase 3

Completed

Conditions: Meningitis
Meningococcal Meningitis
Meningococcal Infections

Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate
Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine

First Posted Date: 2017-03-13

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1000

Registration Number: NCT03077438

Locations: 🇵🇷
Investigational Site, San Juan, Puerto Rico

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Phase 3

Completed

Conditions: Dengue Fever
Dengue Hemorrhagic Fever
Human Papillomavirus Disease

Interventions: Biological: CYD Dengue Vaccine
Biological: Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.

First Posted Date: 2016-12-15

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 528

Registration Number: NCT02993757

Locations: 🇲🇾
Sanofi Pasteur Investigational Site 004, Klang, Malaysia
🇲🇾
Sanofi Pasteur Investigational Site 005, Kuala Lumpur, Malaysia
🇲🇾
Sanofi Pasteur Investigational Site 001, Kuala Lumpur, Malaysia

and more 2 locations

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Phase 3

Terminated

Conditions: Dengue Fever
Dengue Hemorrhagic Fever

Interventions: Biological: CYD Dengue Vaccine

First Posted Date: 2016-12-14

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 688

Registration Number: NCT02992418

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Phase 3

Completed

Conditions: Dengue Hemorrhagic Fever
Dengue Fever
Human Papillomavirus Disease

Interventions: Biological: CYD Dengue Vaccine
Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant

First Posted Date: 2016-12-01

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 480

Registration Number: NCT02979535

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Phase 3

Completed

Conditions: Meningococcal Infections
Meningitis
Meningococcal Meningitis

Interventions: Biological: Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

First Posted Date: 2016-11-04

Last Posted Date: 2022-04-05

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 918

Registration Number: NCT02955797

Locations: 🇫🇮
Investigational Site 306, Helsinki, Finland
🇫🇮
Investigational Site 310, Turku, Finland
🇫🇮
Investigational Site 305, Seinäjoki, Finland

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy